Home › Research › Topics › p-tau217
p-tau217
701 studies tagged p-tau217, dated 1989-01-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival 2026-11-01
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study 2026-11-01
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease 2026-10-30
Studies
701 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 123
- Journal of Alzheimer's disease : JAD 53
- Alzheimer's & dementia (Amsterdam, Netherlands) 46
- Alzheimer's research & therapy 36
- medRxiv 29
196 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
There was a direct and indirect bidirectional effect through the glial fibrillary acidic protein of WMH on phosphorylated tau 217 concentration, which was associated with neurofilament light chain concentration in the entire sample.
-
Blood-based biomarkers of neurodegeneration demonstrate great promise for the diagnosis and prognosis of Alzheimer's disease.
-
Plasma biomarkers of dementia, including phosphorylated tau (p-tau217), offer promise as tools for diagnosis, stratification for clinical trials, monitoring disease progression, and assessing the success of interventions in those living with Alzheimer's disease.
-
Elevated CSF p-tau181 and cortical 18F-PI-2620 binding was characteristic for AD while normal CSF p-tau181 with elevated subcortical 18F-PI-2620 binding was characteristic for 4RTs. 18F-PI-2620-assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.
-
68/100
Across cohorts, the main biomarker associated with α-synuclein positivity at baseline was higher levels of Aβ pathology (all p values ≤ 0.02), but not tau.
-
While blood-based tests are readily available for various conditions, including cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) and other neurodegenerative diseases lack an early blood-based screening test that can be used in primary care.
-
Plasma p-tau181 level showed certain discrepancies between NC and MCI (p < 0.05), AD (p < 0.01) groups.
-
Blood biomarkers are minimally invasive, are available at a relatively low cost, and are easily accessible; therefore, they are expected to play a pivotal role in the diagnosis of dementia.
-
The CSF A/T profiles included 49 A+/T+, 8 A+/T-, and 41 A-/T-.
-
Glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) are putative non-amyloid biomarkers indicative of ongoing inflammatory and neurodegenerative disease processes.
-
Amyloid plaques and tau tangles are the hallmark pathologic features of Alzheimer's disease (AD).
-
52/100
Plasma A+/T + individuals showed the highest levels of astrocyte reactivity, Aβ plaque, tau tangle, and axonal degeneration, and the lowest hippocampal volume and temporal-metaROI cortical thickness.
-
None of the three plasma biomarker was associated with NPS at baseline.
-
This study provides a systematic framework for selection of assay-specific cutpoints for clinical use of plasma p-tau217 for determination of amyloid status.
-
Dementia is a group of symptoms including memory loss, language difficulties, and other types of cognitive and functional impairments that affects 57 million people worldwide, with the incidence expected to double by 2040.
-
Only a few individuals were A+T+Ng-. A+T+Ng+ and A+T+NfL+ showed different proteomic profiles compared to A+T+Ng- and A+T+NfL-, respectively.
-
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon.
-
46/100
CKD patients showed elevated levels of neurofilament light (117 ± 72 vs. 11 ± 5 pg/mL), phosphorylated tau 181 (75 ± 42 vs. 13 ± 8 pg/mL), glial fibrillary acidic protein (193 ± 127 vs. 94 ± 39 pg/mL), amyloid β 42 (17 ± 5 vs. 5 ± 1 pg/mL), and amyloid β 40 (259 ± 96 vs. 72 ± 17 pg/mL) compared to controls.
-
Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups.
-
We detected a significant correlation between AßX-42/X-40 in plasma and CSF (r = 0.473).
-
Alzheimer's Disease (AD) biomarker measurement is key to aid in the diagnosis and prognosis of the disease.
-
Neurological damage is the pathological substrate of permanent disability in various neurodegenerative disorders.
-
CSF exhibited increased levels of all SIMOA biomarkers in AD compared to Controls (AUCs: 0.71, 0.86, 0.92, and 0.94, respectively).
-
46/100
Eighty (22%) participants were APOE ε4 carriers and 290 (73%) were non-carriers.
-
Neurodegenerative disorders such as Alzheimer's disease (AD) represent an increasingly significant public health concern.
-
We found eight flortaucipir covariance patterns which were reproducible and overlapped with relevant gene expression maps.
-
46/100
An accurate diagnosis of neurodegenerative disease and traumatic brain injury is important for prognostication and treatment.
-
Recent technological advances have improved the sensitivity and specificity of blood-based biomarkers for Alzheimer's disease and related dementias.
-
Multivariable models (p-tau+GFAP+NfL) had the best performance to detect Aβ+ in NormCog (ROCAUC = 0.87) and ImpCog (ROCAUC = 0.87).
-
In general linear models lower plasma Aβ42/40 was related to lower visuospatial ability, higher total tau was related to lower episodic memory, and higher NfL was related to lower visuospatial ability and lower episodic memory.
-
These findings show how online testing can now be deployed in patients with AD to measure cognitive function effectively and related to blood biomarkers of the disease.
-
Lower estimated glomerular filtration rate (eGFR) was associated with lower amyloid beta (Aβ)42/tau ratio (p < 0.0001) and Aβ42 (p = 0.002) and higher tau (p < 0.0001) and p-tau (p = 0.0002).
-
During the follow-up, 151 participants developed dementia, of whom 108 had Alzheimer disease (AD) and 43 non-Alzheimer dementia (non-AD).
-
GFAP, NfL and pTau 181 levels in plasma were lower in SCD and MCI than in AD patients.
-
The escalating prevalence of Alzheimer's disease (AD) highlights the urgent need to develop reliable biomarkers for early diagnosis and intervention.
-
46/100
GFAP did not correlate with Aβ- or tau-PET cross-sectionally.
-
Both plasma p-tau217 assays were strongly associated with amyloid and tau PET.
-
Blood-based biomarkers are highly associated with amyloid PET/CSF results in diverse populations enrolled at clinical trial sites.
-
Age was the strongest risk factor for progression.
-
Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET.
-
Dementia represents a growing public health burden with large social, racial, and ethnic disparities.
-
Pairwise comparisons among the three groups showed that compared with the health checkup (HC) group, serum NfL and GFAP were increased in both AD and MCI (PNfL < 0.05, PGFAP < 0.01).
-
Our data suggest that measuring blood biomarkers related to AD pathology and neurodegeneration from DPS venous extends the utility of blood-based biomarkers to remote settings with simplified sampling conditions, storage, and logistics.
-
Alzheimer's disease (AD), a primary cause of dementia globally, is traditionally diagnosed via cerebrospinal fluid (CSF) measures and positron emission tomography (PET).
-
Major depressive disorder (MDD) is a prevalent brain disorder affecting more than 2% of the world's population.
-
Combinations of plasma and digital cognitive markers show promise for scalable diagnosis and prognosis of ADRD.
-
Recent advances in blood-based biomarkers of Alzheimer's Disease (AD) show great promise for clinical applications, offering a less invasive alternative to current cerebrospinal fluid (CSF) measures.
-
Plasma p-tau217 demonstrated better performance in the identification of AD pathology and clinical phenotypes in comparison with other variants of p-tau in a memory clinic cohort.
-
Nineteen participants developed AD after a median of 60 months (interquartile range 30).
-
Ethics Review began a decade ago with a mission to identify ethical concerns that hold back innovation and to promote solutions that would move the field forward.
From across this tag
10 of the 699 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Tailoring thresholds for interpreting plasma p-tau217 levels
- Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease
- Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
- Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease
- Plasma neurofilament light reflects more severe manifestation of Alzheimer's disease in men
- Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders
- Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease
- Design and feasibility of an Alzheimer's disease blood test study in a diverse community-based population
- Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease
- Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study